Evidence map›Paper›PMID 34959347›Full record

ArticlePharmaceutics2021

The Artemiside-Artemisox-Artemisone-M1 Tetrad: Efficacies against Blood Stage

Liezl Gibhard, Dina Coertzen, Janette Reader, Mariëtte E van der Watt, Lyn-Marie Birkholtz, Ho Ning Wong, Kevin T Batty, Richard K Haynes, Lubbe Wiesner

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Liezl GibhardH3D, Department of Chemistry, University of Cape Town, Observatory, Cape Town 7925, South Africa.
Dina CoertzenMalaria Parasite Molecular Laboratory, Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0028, South Africa.ORCID 0000-0002-8408-244X
Janette ReaderMalaria Parasite Molecular Laboratory, Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0028, South Africa.ORCID 0000-0001-9026-0583
Mariëtte E van der WattMalaria Parasite Molecular Laboratory, Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0028, South Africa.
Lyn-Marie BirkholtzMalaria Parasite Molecular Laboratory, Department of Biochemistry, Genetics and Microbiology, Institute for Sustainable Malaria Control, University of Pretoria, Pretoria 0028, South Africa.ORCID 0000-0001-5888-2905
Ho Ning WongCentre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa.
Kevin T BattyCurtin Medical School, Curtin University, Bentley 6102, Australia.ORCID 0000-0003-3850-1778
Richard K HaynesCentre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom 2520, South Africa.ORCID 0000-0001-8554-1823
Lubbe WiesnerDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory, Cape Town 7925, South Africa.ORCID 0000-0002-9070-8699
University of Pretoria · ZANorth-West University · ZAUniversity of Cape Town · ZACurtin University · AU

Funding

SA NRF South African Research Chairs Initiative (SARChI) Grant UID 84627South African Medical Research Council MRC-RFA-UFSP-01-2013South African National Research Foundation UID 129135
6 · The paper itself

Abstract

Because of the need to replace the current clinical artemisinins in artemisinin combination therapies, we are evaluating fitness of amino-artemisinins for this purpose. These include the thiomorpholine derivative artemiside obtained in one scalable synthetic step from dihydroartemisinin (DHA) and the derived sulfone artemisone. We have recently shown that artemiside undergoes facile metabolism via the sulfoxide artemisox into artemisone and thence into the unsaturated metabolite M1; DHA is not a metabolite. Artemisox and M1 are now found to be approximately equipotent with artemiside and artemisone in vitro against asexual

Indexed as

ACTsamino-artemisininsantimalarial drugsartemisininsCmaxdrug efficacymetabolismpharmacokineticsresistance

Identifiers

PMID34959347
PMCPMC8704606
OpenAlexW4226218097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.